Literature DB >> 19924495

Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid.

H Kaji1, M Yamauchi, T Yamaguchi, T Sugimoto.   

Abstract

SUMMARY: Urinary deoxypyridinoline (DPD) level was associated with prevalent vertebral fractures in glucocorticoid (GC)-treated postmenopausal women independently of lumbar spine bone mineral density (BMD).
INTRODUCTION: Bone metabolic indices are the potential predictors of bone fragility. However, their diagnostic efficiency for identifying the risk of GC-induced vertebral fractures is still unclear. We therefore evaluated whether bone metabolic indices would assess the risk of vertebral fractures in GC-treated women.
METHODS: One hundred seventy-five women treated with GC for more than 6 months were enrolled in this study.
RESULTS: Both premenopausal and postmenopausal women with vertebral fractures had significantly higher urinary DPD levels than those without vertebral fractures. When multivariable logistic regression analysis was performed with the presence of vertebral fractures as a dependent variable and each of DPD or osteocalcin level adjusted for age, weight, height, current and maximum doses of GC, duration of GC treatment, as well as lumbar spine BMD as an independent variable, DPD level was identified as a factor associated with the presence of vertebral fractures in postmenopausal women but not in premenopausal women.
CONCLUSION: Urinary DPD level was significantly associated with prevalent vertebral fractures in GC-treated postmenopausal women independently of lumbar spine BMD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19924495     DOI: 10.1007/s00198-009-1108-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  27 in total

Review 1.  Osteoporosis in Cushing's syndrome.

Authors:  Gregory Kaltsas; Luca Manetti; Ashley B Grossman
Journal:  Front Horm Res       Date:  2002       Impact factor: 2.606

2.  Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004).

Authors:  Hajime Nawata; Satoshi Soen; Ryoichi Takayanagi; Ikuko Tanaka; Kunio Takaoka; Masao Fukunaga; Toshio Matsumoto; Yasuo Suzuki; Hiroyuki Tanaka; Saeko Fujiwara; Takami Miki; Akira Sagawa; Yoshiki Nishizawa; Yoshiki Seino
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

3.  Body composition and vertebral fracture risk in female patients treated with glucocorticoid.

Authors:  H Kaji; T Tobimatsu; J Naito; M-F Iu; M Yamauchi; T Sugimoto; K Chihara
Journal:  Osteoporos Int       Date:  2005-12-31       Impact factor: 4.507

Review 4.  Biochemical markers in glucocorticoid-induced osteoporosis.

Authors:  S Minisola; R Del Fiacco; S Piemonte; M Iorio; M L Mascia; F Fidanza; C Cipriani; I Raso; M L Porfiri; C M Francucci; E D'Erasmo; E Romagnoli
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

5.  The usefulness of bone metabolic indices for the prediction of changes in bone mineral density after parathyroidectomy in patients with primary hyperparathyroidism.

Authors:  H Kaji; R Nomura; M Yamauchi; K Chihara; T Sugimoto
Journal:  Horm Metab Res       Date:  2006-06       Impact factor: 2.936

6.  Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing's syndrome.

Authors:  K Godang; T Ueland; J Bollerslev
Journal:  Eur J Endocrinol       Date:  1999-08       Impact factor: 6.664

Review 7.  Use of oral corticosteroids and risk of fractures.

Authors:  T P Van Staa; H G Leufkens; L Abenhaim; B Zhang; C Cooper
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

8.  Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.

Authors:  A R Hermus; A G Smals; L M Swinkels; D A Huysmans; G F Pieters; C F Sweep; F H Corstens; P W Kloppenborg
Journal:  J Clin Endocrinol Metab       Date:  1995-10       Impact factor: 5.958

9.  Bone metabolism and mass in women with Cushing's syndrome and adrenal incidentaloma.

Authors:  Cristiano Maria Francucci; Paola Pantanetti; Gabriella Giuseppina Garrapa; Fernando Massi; Giorgio Arnaldi; Franco Mantero
Journal:  Clin Endocrinol (Oxf)       Date:  2002-11       Impact factor: 3.478

10.  The course of biochemical parameters of bone turnover during treatment with corticosteroids.

Authors:  M F Prummel; W M Wiersinga; P Lips; G T Sanders; H P Sauerwein
Journal:  J Clin Endocrinol Metab       Date:  1991-02       Impact factor: 5.958

View more
  3 in total

Review 1.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.

Authors:  S Lekamwasam; J D Adachi; D Agnusdei; J Bilezikian; S Boonen; F Borgström; C Cooper; A Diez Perez; R Eastell; L C Hofbauer; J A Kanis; B L Langdahl; O Lesnyak; R Lorenc; E McCloskey; O D Messina; N Napoli; B Obermayer-Pietsch; S H Ralston; P N Sambrook; S Silverman; M Sosa; J Stepan; G Suppan; D A Wahl; J E Compston
Journal:  Osteoporos Int       Date:  2012-03-21       Impact factor: 4.507

2.  Discriminants of prevalent fractures in chronic kidney disease.

Authors:  Thomas L Nickolas; Serge Cremers; Amy Zhang; Valeri Thomas; Emily Stein; Adi Cohen; Ryan Chauncey; Lucas Nikkel; Michael T Yin; Xiaowei S Liu; Stephanie Boutroy; Ronald B Staron; Mary B Leonard; Donald J McMahon; Elzbieta Dworakowski; Elizabeth Shane
Journal:  J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 10.121

3.  Alterations of bone geometry, density, microarchitecture, and biomechanical properties in systemic lupus erythematosus on long-term glucocorticoid: a case-control study using HR-pQCT.

Authors:  X L Tang; L Qin; A W Kwok; T Y Zhu; E W Kun; V W Hung; J F Griffith; P C Leung; E K Li; L-S Tam
Journal:  Osteoporos Int       Date:  2012-10-27       Impact factor: 4.507

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.